(VIANEWS) – ALMUNDA PRO NV (AMUND.AS), AKER BP (AKRBP.OL), CAIRN HOMES PLC (C5H.IR) are the highest payout ratio stocks on this list.
We have congregated information about stocks with the highest payout ratio as yet. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. ALMUNDA PRO NV (AMUND.AS)
239.91% Payout Ratio
Almunda Professionals N.V., a business and IT consultancy company, provides business services in the financial sector. It offers consultancy services in the areas of regulatory change, digital transformation, information security, and information services. The company was formerly known as Novisource N.V. and changed its name to Almunda Professionals N.V. in August 2021. Almunda Professionals N.V. was founded in 2001 and is based in Amsterdam, the Netherlands.
Earnings Per Share
As for profitability, ALMUNDA PRO NV has a trailing twelve months EPS of €0.02.
PE Ratio
ALMUNDA PRO NV has a trailing twelve months price to earnings ratio of 65.5. Meaning, the purchaser of the share is investing €65.5 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.17%.
Yearly Top and Bottom Value
ALMUNDA PRO NV’s stock is valued at €1.31 at 17:10 EST, way below its 52-week high of €1.60 and way above its 52-week low of €1.17.
More news about ALMUNDA PRO NV.
2. AKER BP (AKRBP.OL)
98.87% Payout Ratio
Aker BP ASA explores for, develops, and produces oil and gas on the Norwegian Continental Shelf. The company was formerly known as Det norske oljeselskap ASA and changed its name to Aker BP ASA in October 2016. Aker BP ASA was founded in 2001 and is headquartered in Fornebu, Norway.
Earnings Per Share
As for profitability, AKER BP has a trailing twelve months EPS of kr21.44.
PE Ratio
AKER BP has a trailing twelve months price to earnings ratio of 12.87. Meaning, the purchaser of the share is investing kr12.87 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.94%.
Volume
Today’s last reported volume for AKER BP is 658508 which is 42.89% below its average volume of 1153240.
Revenue Growth
Year-on-year quarterly revenue growth grew by 46.8%, now sitting on 14.03B for the twelve trailing months.
More news about AKER BP.
3. CAIRN HOMES PLC (C5H.IR)
50.88% Payout Ratio
Cairn Homes plc operates as a homebuilder in Ireland. It is involved in the development and sale of residential properties, as well as rental of properties. The company was incorporated in 2014 and is based in Dublin, Ireland.
Earnings Per Share
As for profitability, CAIRN HOMES PLC has a trailing twelve months EPS of €0.11.
PE Ratio
CAIRN HOMES PLC has a trailing twelve months price to earnings ratio of 10. Meaning, the purchaser of the share is investing €10 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.59%.
Moving Average
CAIRN HOMES PLC’s worth is under its 50-day moving average of €1.10 and way higher than its 200-day moving average of €1.00.
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.5%, now sitting on 617.36M for the twelve trailing months.
Volume
Today’s last reported volume for CAIRN HOMES PLC is 22267 which is 96.89% below its average volume of 717811.
More news about CAIRN HOMES PLC.
4. SANOFI (SAN.PA)
50.08% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.69.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 14.72. Meaning, the purchaser of the share is investing €14.72 for every euro of annual earnings.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 5.2% and a negative 7.7%, respectively.
More news about SANOFI.
